AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
0.680
+0.010 (1.46%)
Jan 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.63 - 0.68
52 week 0.54 - 1.23
Open 0.65
Vol / Avg. 160,078.00/402,020.00
Mkt cap 53.92M
P/E     -
Div/yield     -
EPS -0.44
Shares 75.86M
Beta 0.80
Inst. own 41%
Mar 13, 2017
Q4 2016 Aveo Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Nov 30, 2016
Aveo Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 4, 2016
Q3 2016 Aveo Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -500.60% -78.85%
Operating margin -563.81% -65.32%
EBITD margin - 7.69%
Return on average assets -51.20% -26.98%
Return on average equity -336.86% -79.30%
Employees 19 -
CDP Score - -

Address

One Broadway, 14Th Floor
CAMBRIDGE, MA 02142
United States - Map
+1-617-5312130 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Officers and directors

Michael P. Bailey President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Keith S. Ehrlich CPA Chief Financial Officer
Age: 64
Bio & Compensation  - Reuters
Michael N. Needle M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Henri A. Termeer Lead Out Side Director
Age: 70
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 65
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Robert C. Young M.D. Independent Director
Age: 75
Bio & Compensation  - Reuters